Fulgent Genetics (FLGT): Debts to Book Capitalization

Fulgent Genetics, Inc. (FLGT) is implementing eco-friendly digital protocols in genetics while maintaining strict control over waste disposal. Efficient logistics for transporting biomaterials to central hubs accelerate diagnostic turnaround times. The business relies on oncology diagnostics and IT solutions, resulting in a metric of 0.01. This price chart for the shares of the company, which specializes in laboratory health screening, is provided below.

FLGT Fulgent Debt to Book Value Ratio (07/04/2022 - 10/28/2026)

Summary analytical data breakdowns for Fulgent Genetics Inc (FLGT)

- price and consensus price forecast:

Stock Price Fulgent Genetics, Inc.|FLGT - Broker Consensus Forecast

- market capitalization data:

Market Capitalization Fulgent|FLGT - Enterprise Value

- book capitalization data:

Net Assets per Single Share Fulgent Genetics|FLGT - Accounting Capitalization|Market Capitalization to Book Value Ratio fulgentgenetics.com|FLGT - Company Total Assets

- debt and liquidity data:

Debt to Equity Fulgent Genetics, Inc.|FLGT - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Fulgent Corp|FLGT - Company Cumulative Debt|Debt to Book Capitalization Ratio Fulgent

Summary company analytics:Fulgent Genetics, Inc.

Fulgent Genetics, Inc. (FLGT) is generating a steady cash flow to service its obligations through the diversification of its oncology diagnostics services and contracts with US clinics. By analyzing the ratio of financial debt to book capitalization, investors assess the proportion of borrowed funds within the equity structure, where a decrease in this coefficient confirms the issuer's financial stability and minimizes bankruptcy risks during market downturns.

Competitors of Fulgent Genetics, Inc.